(Q37308825)

19 August 2017

0 references

1 reference

title

Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis (English)

1 reference

nephrogenic systemic fibrosis

19 August 2017

0 references

1 reference

0 references

1 reference

1 reference

Rajender Agarwal

1

1 reference

19 August 2017

Steven M Brunelli

2

1 reference

19 August 2017

Kendal Williams

3

1 reference

19 August 2017

Matthew D Mitchell

4

1 reference

19 August 2017

Harold I Feldman

5

1 reference

19 August 2017

Craig A Umscheid

6

1 reference

19 August 2017

language of work or name

English

0 references

publication date

24 October 2008

1 reference

Nephrology Dialysis Transplantation

19 August 2017

published in

1 reference

19 August 2017

volume

24

1 reference

19 August 2017

issue

3

1 reference

19 August 2017

page(s)

856-863

1 reference

Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Nephrogenic systemic fibrosis: early recognition and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Nephrogenic fibrosing dermopathy: the first 6 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Nephrogenic systemic fibrosis: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Nephrogenic systemic fibrosis: center case review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Nephrogenic systemic fibrosis: risk factors and incidence estimation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Gadolinium deposition in nephrogenic fibrosing dermopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Bias in location and selection of studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Development and validation of MIX: comprehensive free software for meta-analysis of causal research data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Gadolinium - is it to blame?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

ACR Guidance Document for Safe MR Practices: 2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN593

21 January 2018

Identifiers

DOI

10.1093/NDT/GFN593

1 reference

19 August 2017

1 reference